MDSpire - Summary
From the Journals

Could NPDR Be Treated Orally?

Phase 1b results for danegaptide indicate promising safety profile in patients with non-proliferative diabetic retinopathy and macular edema

  • March 24, 2026

  • 5 min

Share

At the virtual Angiogenesis, Exudation and Degeneration 2026 symposium, Carl Regillo presented promising phase 1b trial results for danegaptide, an oral drug aimed at treating non-proliferative diabetic retinopathy (NPDR). This trial, conducted across 11 sites in the US, Germany, and the UK, evaluated safety, tolerability, and early biological activity in 24 patients. Danegaptide works by stabilizing gap-junctions and counteracting VEGF effects, with potential for earlier interventions, thus addressing a significant unmet need in diabetic eye care.

Original Source(s)

Could NPDR Be Treated Orally?

  • March 24, 2026

Related Content

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials

An overview of key visual and anatomic findings with EYP-1901 from the DAVIO 2 and VERONA clinical trials, presented at Macula Society 2026

  • March 24, 2026

  • 6 min
Why Glaucoma Prevalence Is Rising

... and what the eye care community must do next